{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:09:26Z","timestamp":1791288566910,"version":"4.3.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":811,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.cmi.2021.06.024","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T01:48:00Z","timestamp":1624844880000},"page":"300.e1-300.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China"],"prefix":"10.1016","volume":"28","author":[{"given":"Zonglin","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene O.L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.Y.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.06.024_bib1","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1111\/ajt.15093","article-title":"Access to treatment for hepatitis B virus infection Worldwide, 2016","volume":"18","author":"Hutin","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.06.024_bib2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"The global burden of liver disease: the major impact of China","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2021.06.024_bib3","first-page":"938","article-title":"The guidelines of prevention and treatment for chronic hepatitis B (2019 version)","volume":"27","year":"2019","journal-title":"Chin J Hepatol"},{"key":"10.1016\/j.cmi.2021.06.024_bib4","series-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.cmi.2021.06.024_bib5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2021.06.024_bib6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2021.06.024_bib7","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1524-4733.2010.00733.x","article-title":"Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis","volume":"13","author":"Wu","year":"2010","journal-title":"Value in Health"},{"key":"10.1016\/j.cmi.2021.06.024_bib8","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1111\/j.1572-0241.2006.00769.x","article-title":"Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis","volume":"101","author":"Kanwal","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2021.06.024_bib9","series-title":"World health statistics 2018: monitoring health for the SDGs","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.cmi.2021.06.024_bib10","series-title":"The third affiliated hospital of Sun","year":"2018"},{"key":"10.1016\/j.cmi.2021.06.024_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Org"},{"key":"10.1016\/j.cmi.2021.06.024_bib12","first-page":"1558","article-title":"A\u00a0study of compliance in patients with HBeAg-negative chronic hepatitis B receiving entecavir treatment","volume":"33","author":"Tao","year":"2017","journal-title":"J\u00a0Clin Hepatol"},{"key":"10.1016\/j.cmi.2021.06.024_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2018.1433987","article-title":"Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B","volume":"11","author":"Xu","year":"2018","journal-title":"Glob Health Action"},{"key":"10.1016\/j.cmi.2021.06.024_bib14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/apt.15053","article-title":"Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir","volume":"49","author":"Kuo","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2021.06.024_bib15","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jis569","article-title":"Young chronic hepatitis b patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation","volume":"206","author":"Tai-Chung","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2021.06.024_bib16","article-title":"Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B","author":"Kim","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2021.06.024_bib17","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.cmi.2021.06.024_bib18","first-page":"249","article-title":"A\u00a0potential functional cure in Chinese HBeAg-negative chronic hepatitis B patients treated with Peg-interferon alpha-2a","volume":"7","author":"Xinyue","year":"2019","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.cmi.2021.06.024_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.gastro.2009.09.018","article-title":"Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus E antigen seroconversion","volume":"138","author":"Wu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2021.06.024_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3851\/IMP1497","article-title":"Hepatitis B surface antigen seroclearance during chronic HBV infection","volume":"15","author":"Chu","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2021.06.024_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00042737-200012060-00019","article-title":"Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study","volume":"12","author":"Huo","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2021.06.024_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1440-1746.2005.03813.x","article-title":"Chronic hepatitis B virus infection in the Asia\u2013Pacific region and Africa: review of disease progression","volume":"20","author":"Lin","year":"2005","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2021.06.024_bib23","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.30973","article-title":"Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"71","author":"Goh","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2021.06.024_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.23348","article-title":"Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"51","author":"Chen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2021.06.024_bib25","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ajg.2009.187","article-title":"Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus","volume":"104","author":"Chu","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2021.06.024_bib26","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","article-title":"Hepatitis B virus DNA levels and outcomes in chronic hepatitis B","volume":"49","author":"Chen","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2021.06.024_bib27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1053\/gast.2002.36026","article-title":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection","volume":"123","author":"Chen","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2021.06.024_bib28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2014.11.031","article-title":"Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance","volume":"62","author":"Kim","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2021.06.024_bib29","doi-asserted-by":"crossref","first-page":"342","DOI":"10.5152\/tjg.2016.15535","article-title":"Insight into the natural history of primary biliary cirrhosis: a systemic review of data from placebo-controlled clinical trials","volume":"27","author":"Xu","year":"2016","journal-title":"Turkish J Gastroenterol"},{"key":"10.1016\/j.cmi.2021.06.024_bib30","doi-asserted-by":"crossref","first-page":"42253","DOI":"10.1038\/srep42253","article-title":"Predicting short-term survival after liver transplantation on eight score systems: a national report from China Liver Transplant Registry","volume":"7","author":"Ling","year":"2017","journal-title":"Sci Rep"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2100344X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2100344X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:30:51Z","timestamp":1761118251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2100344X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1198743X2100344X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.06.024","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}